{"id":402026,"date":"2023-12-26T08:57:59","date_gmt":"2023-12-26T13:57:59","guid":{"rendered":"https:\/\/platohealth.ai\/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments-medical-device-news-magazine\/"},"modified":"2023-12-27T14:47:26","modified_gmt":"2023-12-27T19:47:26","slug":"brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments-medical-device-news-magazine","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments-medical-device-news-magazine\/","title":{"rendered":"BrainStorm Granted Patents For Allogeneic Exosome Platform-Product In Neurological Disorder Treatments &#8211; Medical Device News Magazine","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"<div><img decoding=\"async\" src=\"https:\/\/platohealth.ai\/wp-content\/uploads\/2023\/12\/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments-medical-device-news-magazine.png\" class=\"ff-og-image-inserted\"><\/div>\n<div class=\"tdb-block-inner td-fix-index\">\n<h4 id=\"brainstorm-cell-therapeutics-inc-nasdaq-bcli-a-leading-developer-of-adult-stem-cell-therapeutics-for-neurodegenerative-diseases-today-provided-an-update-on-the-grant-and-allowance-of-three-patent-applications-for-nurown\u00ae-and-nurown-exosomes\"><a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/brainstorm-cell.com\/\">Brainstorm Cell Therapeutics Inc.<\/a> (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn\u00ae and NurOwn-Exosomes.<\/h4>\n<p>The European Patent office granted patent No. 3105587 titled \u2018Method of Qualifying of Cells\u2019 for a method of qualifying whether a cell population is a suitable therapeutic for treating ALS. The patent also grants claims for an isolated population of mesenchymal stem cells for use in treating ALS.<\/p>\n<p>The Australian patent Office granted patent No. 2019252987 titled \u2018Cell-Type Specific Exosomes and Use Thereof\u2019 for an isolated Exosomes population derived from MSC-NTF cells as well as a pharmaceutical composition for the treatment of neurodegenerative diseases.<\/p>\n<p>The Israel Patent Office announced the allowance of the same claims for application No. 277447 with an Acceptance date on <span class=\"xn-chron\">December 01, 2023<\/span>.<\/p>\n<p>\u201cWe are committed to fortifying our technological advancements with robust intellectual property strategies,\u201d stated BrainStorm\u2019s CEO, <span class=\"xn-person\">Chaim Lebovits<\/span>. \u201cThe recent acquisition of the European patent for our unique MSC-NTF cell population marks an important step in safeguarding our proprietary NurOwn technology, particularly for ALS treatment. The Australian patent, which is our inaugural grant for the specialized MSC-NTF cell exosomes, represents a pivotal achievement in the evolution of our exosome technology, meticulously crafted by the Brainstorm research team. Securing this European patent, alongside our existing patents in the US, <span class=\"xn-location\">Canada<\/span>, <span class=\"xn-location\">Israel<\/span>, <span class=\"xn-location\">Brazil<\/span>, and <span class=\"xn-location\">Japan<\/span>, enhances our capability to forge new global commercial partnerships, further expanding the reach of NurOwn.\u201d<\/p>\n<\/div>\n<ul class=\"plato-post-bottom-links\">\n<li class=\"plato-post-bottom-link-amplifi\">SEO Powered Content &amp; PR Distribution. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/www.amplifipr.com\">Get Amplified Today.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platodata-network\">PlatoData.Network Vertical Generative Ai. Empower Yourself. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platodata.network\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoaistream\">PlatoAiStream. Web3 Intelligence. Knowledge Amplified. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoaistream.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platoesg\">PlatoESG. <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/carbon\/\">Carbon,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/cleantech\/\">CleanTech,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/energy\/\">Energy,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/environment\/\">Environment,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/solar\/\">Solar,<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\/aiwire\/waste-management\/\">Waste Management.<\/a> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/platoesg.com\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-platohealth\">PlatoHealth. Biotech and Clinical Trials Intelligence. <a href=\"https:\/\/platohealth.ai\" target=\"_blank\" rel=\"noopener\">Access Here.<\/a><\/li>\n<li class=\"plato-post-bottom-link-source\"><span>Source:<\/span> <a rel=\"noopener\" target=\"_blank\" href=\"https:\/\/infomeddnews.com\/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments\/\">https:\/\/infomeddnews.com\/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments\/<\/a><\/li>\n<\/ul>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"excerpt":{"rendered":"<p>Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today provided an update on the grant and allowance of three patent applications for NurOwn\u00ae and NurOwn-Exosomes. The European Patent office granted patent No. 3105587 titled \u2018Method of Qualifying of Cells\u2019 for a method of qualifying whether a [&hellip;]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":402029,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[52],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/402026"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=402026"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/402026\/revisions"}],"predecessor-version":[{"id":402028,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/402026\/revisions\/402028"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/402029"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=402026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=402026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=402026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}